Incretins and the development of type 2 diabetes

被引：69

作者：

Meier J.J. ^{[1
]}

Nauck M.A. ^{[1
]}

机构：

[1] Diabeteszentrum Bad Lauterberg, D-37431 Bad Lauterberg im Harz

来源：

Current Diabetes Reports | 2006年 / 6卷 / 3期

关键词：

Insulin Secretion; Impaired Glucose Tolerance; Gastric Inhibitory Polypeptide; Incretin Hormone; Incretin Effect;

D O I：

10.1007/s11892-006-0034-7

中图分类号：

学科分类号：

摘要：

The incretin hormones gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are released in response to nutrient ingestion and potentiate glucose-stimulated insulin secretion from pancreatic β cells. The augmentation of postprandial insulin secretion by such gastrointestinal hormones is called the incretin effect. The incretin effect is almost completely absent in patients with type 2 diabetes. This is due to 1) an approximate 15% reduction in postprandial GLP-1 secretion and 2) a near total loss of insulinotropic activity of GIP. This review article summarizes clinical studies on abnormalities in the secretion and insulinotropic effects of GIP and GLP-1 in patients with type 2 diabetes as well as in individuals at high risk. A significant proportion of first-degree relatives are characterized by a reduced insulinotropic response to exogenous GIP. Nevertheless, this phenomenon does not predispose to a more rapid deterioration in glucose tolerance or conversion to impaired glucose tolerance or diabetes. Therefore, although there are hints of early abnormalities in incretin secretion and action in prediabetic populations, it has not been proven that such phenomena are central to the pathogenesis of type 2 diabetes. Copyright © 2006 by Current Science Inc.

引用

页码：194 / 201

页数：7

共 75 条

[1]

Moore B., Edie E.S., Abram J.H., On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane, Biochem J, 1, pp. 28-38, (1906)

[2]

Berson S.A., Yallow R.S., Immunoassay of plasma insulin, Ciba Found Colloquia Endocrinol, 41, pp. 182-201, (1962)

[3]

Perley M.J., Kipnis D.M., Plasma insulin responses to oral and intravenous glucose: Studies in normal and diabetic subjects, J Clin Invest, 46, pp. 1954-1962, (1967)

[4]

Nauck M.A., Homberger E., Siegel E.G., Et al., Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses, J Clin Endocrinol Metab, 63, pp. 492-498, (1986)

[5]

Creutzfeldt W., The incretin concept today, Diabetologia, 16, pp. 75-85, (1979)

[6]

Brown J.C., Pederson R.A., Jorpes E., Mutt V., Preparation of highly active enterogastrone, Can J Physiol Pharmacol, 47, pp. 113-114, (1969)

[7]

Brown J.C., Dryburgh J.R., A gastric inhibitory polypeptide II. The complete amino acid sequence, Can J Biochem, 49, pp. 867-872, (1971)

[8]

Buchan A.M.J., Polak J.M., Capella C., Et al., Electron immunocytochemical evidence of the K cell localisation of gastric inhibitory polypeptide (GIP) in man, Histochemistry, 56, pp. 37-44, (1978)

[9]

Buffa B., Polak J.M., Pearse A.G.E., Et al., Identification of the intestinal cell storing gastric inhibitory polypeptide, Histochemistry, 43, pp. 249-255, (1975)

[10]

Krarup T., Immunoreactive gastric inhibitory polypeptide, Endocr Rev, 9, pp. 122-133, (1988)

← 1 2 3 4 5 6 7 8 →